Cargando…

Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients

Detalles Bibliográficos
Autores principales:	Liebers, Nora, Speer, Claudius, Benning, Louise, Bruch, Peter-Martin, Kraemer, Isabelle, Meissner, Julia, Schnitzler, Paul, Kräusslich, Hans-Georg, Dreger, Peter, Mueller-Tidow, Carsten, Poschke, Isabel, Dietrich, Sascha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology. 2022
Materias:	Letters to Blood
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8530768/ https://www.ncbi.nlm.nih.gov/pubmed/34669919 http://dx.doi.org/10.1182/blood.2021013445

Ejemplares similares

Seroconversion Rates After the Second COVID-19 Vaccination in Patients With Systemic Light Chain (AL) amyloidosis
por: Liebers, Nora, et al.
Publicado: (2022)

Humoral Responses and Chronic GVHD Exacerbation after COVID-19 Vaccination Post Allogeneic Stem Cell Transplantation
por: Pabst, Caroline, et al.
Publicado: (2022)

Comparing the value of mono- vs coculture for high-throughput compound screening in hematological malignancies
por: Herbst, Sophie A., et al.
Publicado: (2023)

Response to Vaccination with Sars-CoV2 Vaccines in Patients Post Allogeneic Hematopoietic Cell Transplantation
por: Pabst, Caroline, et al.
Publicado: (2022)

Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies
por: Ghione, Paola, et al.
Publicado: (2021)

Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy
por: Terpos, Evangelos, et al.
Publicado: (2022)

Nanofiltration as a robust method contributing to viral safety of plasma‐derived therapeutics: 20 yearsʼ experience of the plasma protein manufacturers
por: Roth, Nathan J., et al.
Publicado: (2020)

Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol
por: Schubert, Maria-Luisa, et al.
Publicado: (2019)

Biochemical comparison of four commercially available C1 esterase inhibitor concentrates for treatment of hereditary angioedema
por: Feussner, Annette, et al.
Publicado: (2014)

Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks
por: Speer, Claudius, et al.
Publicado: (2021)

Barriers to blood donation on social media: An analysis of Facebook and Twitter posts
por: Ramondt, Steven, et al.
Publicado: (2020)

Pathogen reduction of double‐dose platelet concentrates from pools of eight buffy coats: Product quality, safety, and economic aspects
por: Rosskopf, Konrad, et al.
Publicado: (2020)

Immune thrombocytopenic purpura after vaccination with COVID-19 vaccine (ChAdOx1 nCov-19)
por: Paulsen, Finn-Ole, et al.
Publicado: (2021)

VEXAS syndrome
por: Grayson, Peter C., et al.
Publicado: (2021)

Cure of intravascular NK/T-cell lymphoma of the central nervous system by allogeneic hematopoietic cell transplantation
por: Meissner, Julia, et al.
Publicado: (2022)

The use of IV immunoglobulin in the treatment of vaccine-induced immune thrombotic thrombocytopenia
por: Uzun, Günalp, et al.
Publicado: (2021)

Heterologous ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses among Health Care Workers
por: Benning, Louise, et al.
Publicado: (2021)

Robust inactivation of Plasmodium falciparum in red blood cell concentrates using amustaline and glutathione pathogen reduction
por: Sow, Cissé, et al.
Publicado: (2022)

Performance characteristics of a novel blood bag in-line closure device and subsequent product quality assessment
por: Serrano, Katherine, et al.
Publicado: (2010)

Failure of self-disclosure of deferrable risk behaviors associated with transfusion-transmissible infections in blood donors
por: Wong, Horas Tze Hoo, et al.
Publicado: (2015)

Detection, characterization, and enrollment of donors of Ebola convalescent plasma in Sierra Leone
por: Tedder, Richard S., et al.
Publicado: (2018)

Estimation of the number of blood donors during the COVID‐19 incubation period across China and analysis of prevention and control measures for blood transfusion transmission
por: Yuan, Zhaohu, et al.
Publicado: (2020)

Deferral rate variability in blood donor eligibility assessment
por: de Kort, Wim, et al.
Publicado: (2018)

Ensuring HLA‐matched platelet support requires an ethnic diverse donor population
por: Kreuger, Aukje L., et al.
Publicado: (2020)

First results of a ferritin‐based blood donor deferral policy in the Netherlands
por: Vinkenoog, Marieke, et al.
Publicado: (2020)

Determinants of blood donation willingness in the European Union: a cross‐country perspective on perceived transfusion safety, concerns, and incentives
por: Huis in ‘t Veld, Elisabeth M.J., et al.
Publicado: (2019)

Prediction paradigm involving time series applied to total blood issues data from England
por: Nandi, Anita K., et al.
Publicado: (2020)

Do deferred donors continue their donations? A large‐scale register study on whole blood donor return in the Netherlands
por: Spekman, Marloes L.C., et al.
Publicado: (2019)

Frequent platelet donation is associated with lymphopenia and risk of infections: A nationwide cohort study
por: Zhao, Jingcheng, et al.
Publicado: (2020)

Whole blood donor behavior and availability after deferral: Consequences of a new ferritin monitoring policy
por: Spekman, Marloes L.C., et al.
Publicado: (2020)

Risk of hematological malignancy in blood donors: A nationwide cohort study
por: Zhao, Jingcheng, et al.
Publicado: (2020)

New blood donors in times of crisis: Increased donation willingness, particularly among people at high risk for attracting SARS‐CoV‐2
por: Spekman, Marloes L. C., et al.
Publicado: (2021)

Assessment of serological assays for identifying high titer convalescent plasma
por: Farnsworth, Christopher W., et al.
Publicado: (2021)

Personalized collection of plasma from healthy donors: A randomized controlled trial of a novel technology‐enabled nomogram
por: Hartmann, Jan, et al.
Publicado: (2021)

Staff perspectives on barriers and enablers to implementing alternative source plasma eligibility criteria for gay, bisexual, and other men who have sex with men
por: Castillo, Gisell, et al.
Publicado: (2022)

How to increase first‐time donors' returns? The postdonation letter's content can make a difference
por: Moussaoui, Lisa S., et al.
Publicado: (2022)

Sexual risk behavior questions: Understanding and mitigating donor discomfort
por: Haw, Jennie, et al.
Publicado: (2021)

Mitigating the risk of transfusion‐transmitted infections with vector‐borne agents solely by means of pathogen reduction
por: Stramer, Susan L., et al.
Publicado: (2022)

Plasmavigilance—Adverse events among US Source plasma donors
por: Schreiber, George B., et al.
Publicado: (2021)

A robust autonomous method for blood demand forecasting
por: Turkulainen, Esa V., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rl6jnqf958spf8pncpuvikpf0u